Skip to main content
Triangle logo TriangleGet started

Stereotactic Radiation (NCT04899908)

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases: a one-minute explainerNCT048999081 min

Stereotactic Radiation trial for Brain Cancer (NCT04899908). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with brain metastases from solid cancers and specified features affecting control. Criteria concern cancer type, size, cystic change or recurrence after radiation. MRI and gadolinium tolerance are required.

The idea: AGuIX gadolinium nanoparticles are intended to increase tumors’ response to focused radiation. Random assignment adds nanoparticle injections or placebo before and during stereotactic radiation. Researchers measure local recurrence at six months. Previous radiation requires safety review.

This phase 2 study plans 134 patients. Ayal Aizer leads it; two Boston sites, Brigham and Women’s and Dana-Farber, are recruiting.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.